Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th.
ENPNewswire-October 26, 2023--Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th
(C)2023 ENPublishing - http://www.enpublishing.co.uk
Release date- 25102023 - SAN FRANCISCO - Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ: JAGX) family company, today announced that on December 7, 2023, the company will present results from its pivotal Phase 3 OnTarget study of Napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the San Antonio Breast Cancer Symposium (SABCS).
Napo expects to announce top line results of the trial by the Thanksgiving holiday.
Since 1977, SABCS has been the leading scientific conference for scientists, physicians, clinical investigators, breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer.
'We are very happy to have been accepted to present the important results of the OnTarget trial at SABCS this December,' said Lisa Conte, Jaguar's president and CEO. 'Diarrhea is a common occurrence with targeted therapies such as tyrosine kinase inhibitors, EGFR, HER2 and PARP inhibitors, and immunotherapy, and can also occur with chemotherapy. More than 80 oral targeted cancer therapies are FDA approved, many of which cause diarrhea in 50-100% of patients.'
More than 1 million cancer patients in the US receive chemotherapy or radiation each year,1 according to the Centers for Disease Control and Prevention (CDC). Cancer patients with diarrhea have been shown to be 40% more likely to discontinue their targeted therapy.2 The OnTarget study is testing whether crofelemer (versus placebo) can prevent (or substantially reduce) diarrhea when any one of 24 different targeted therapies (that are associated with diarrhea in at least 50% of patients) is started.
About the Phase 3 OnTarget Clinical Trial
The multicenter double-blind, placebo-controlled OnTarget study is a first-of-its-kind prophylactic clinical trial with a primary endpoint based on patient-reported outcomes that address the high unmet burden of cancer therapy-related diarrhea (CTD). Debilitating diarrhea (loose and/or watery stools), fecal incontinence, and...
To continue reading
Request your trial